Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
J Chemother. 2021 Dec;33(8):564-569. doi: 10.1080/1120009X.2021.1913702. Epub 2021 May 24.
Ovarian cancer is the leading cause of death from gynecologic cancers, but platinum resistance remains a major obstacle in the chemotherapy of ovarian cancer. This study aims to examine the role of polymorphisms in sulfatase 1 () in platinum resistance and survival in advanced epithelial ovarian cancer (EOC) patients. We genotyped 12 SNPs of in 195 EOC patients treated with platinum using MassARRAY method and evaluated the association between the SNPs and platinum response. rs3802278 was marginal significantly associated with platinum resistance in recessive model with p value of 0.055. The patients with rs3802278 AA were more resistant to platinum-based chemotherapy comparing to those with AG/GG genotype (OR: 2.317, 95%CI: 0.982 ∼ 5.465). In survival analysis, rs3802278 was significantly associated with both of PFS and OS after adjusted by FIGO stage and age. Patients with AA genotypes showed a shorter PFS and OS than with AG/GG genotypes (median PFS: 15 months vs. 21 months, = 0.010, HR = 1.876, 95%CI: 1.165-3.022; median OS: 42 months vs. 73 months, = 0.031, HR = 1.928, 95%CI: 1.061-3.504). rs3802278 may serve as a potential candidate biomarker for the prediction of platinum resistance and prognosis in Chinese EOC patients.
卵巢癌是妇科癌症死亡的主要原因,但铂类耐药仍然是卵巢癌化疗的主要障碍。本研究旨在探讨磺基转移酶 1 () 多态性在晚期上皮性卵巢癌 (EOC) 患者铂类耐药和生存中的作用。我们使用 MassARRAY 方法对 195 例接受铂类化疗的 EOC 患者的 12 个 SNPs 进行了基因分型,并评估了 SNPs 与铂类反应之间的关系。在隐性模型中,rs3802278 与铂类耐药呈边缘显著相关,p 值为 0.055。与 AG/GG 基因型相比,rs3802278AA 基因型的患者对铂类为基础的化疗更耐药(OR:2.317,95%CI:0.982~5.465)。在生存分析中,rs3802278 在调整 FIGO 分期和年龄后,与 PFS 和 OS 均显著相关。AA 基因型患者的 PFS 和 OS 均短于 AG/GG 基因型患者(中位 PFS:15 个月比 21 个月,P=0.010,HR=1.876,95%CI:1.165-3.022;中位 OS:42 个月比 73 个月,P=0.031,HR=1.928,95%CI:1.061-3.504)。rs3802278 可能成为中国 EOC 患者预测铂类耐药和预后的潜在候选生物标志物。